A new sweat sensor device for diagnosing cystic fibrosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates a novel skin-interfaced colorimetric bifluidic sweat sensor designed to improve the diagnosis of cystic fibrosis (CF). The device aims to provide a low-cost and accurate alternative to the traditional sweat chloride test, which has limitations such as insufficient sweat volume and complexity in young patients. Participants will include adults with a known diagnosis of CF or healthy volunteers, and the device's performance will be compared to standard laboratory procedures at Penn State Health Milton S. Hershey Medical Center. The goal is to enhance the accuracy and accessibility of CF diagnosis through real-time sweat analysis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* adults 18 years of age or older capable of providing signed and dated informed consent,
* subjects with an established known diagnosis of cystic fibrosis (CF) or healthy volunteers,
* able to understand and speak English language.

Exclusion Criteria:

* any medical condition or disorder known to potentially interfere with accurate measurements of sweat chloride
* inability to understand and speak the English language.

Where it's running

• Penn State Milton S. Hershey Medical Center
  Hershey, Pennsylvania, United States Recruiting

Study contacts

• Study coordinator: Robert Vender
• Email: rvender@pennstatehealth.psu.edu
• Phone: 17175316525

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Inhaled CFTR mRNA for cystic fibrosis in Chinese patients aged 12 and older

  This trial tests inhaled BMD003, a CFTR mRNA therapy, to see if it's safe and shows early signs of benefit in Chinese people 12 years and up with cystic fibrosis.

  Recruiting Early Phase 1 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07485543

• VX-272 dose escalation in healthy adults

  This will test single and multiple increasing doses of the experimental drug VX-272 in healthy adults to see how safe it is and how the body handles it.

  Recruiting Phase 1 Vertex Pharmaceuticals Incorporated · Tempe, Arizona · NCT07437105

• Prevalence of smoking, passive smoke exposure, and vaping among adults with cystic fibrosis

  This project will see how common smoking, exposure to secondhand smoke, and vaping are among adults with cystic fibrosis followed at the Strasbourg Adult CF Center.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07342920

• Dose escalation of VX-581 to check safety and drug levels in healthy adults

  The trial will test increasing doses of VX-581 in healthy adults to see if it is safe and to measure how the body absorbs and clears the drug.

  Recruiting Phase 1 Vertex Pharmaceuticals Incorporated · Overland Park, Kansas · NCT07283770

• PALMIRE cohort: phenotyping inflammatory lung diseases to enable personalized care

  This project will collect clinical, imaging, and biological data from adults with asthma, COPD, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, or interstitial lung disease to try to identify disease subtypes and markers that could guide more personalized care.

  Recruiting CHU de Reims · Reims · NCT07274631

• Collecting sputum samples at home for cystic fibrosis patients

  This study is testing if collecting sputum samples at home can help people with cystic fibrosis better identify lung infections compared to traditional methods done at the clinic.

  Recruiting at 4 sites University of Pennsylvania · Denver, Colorado and 3 other locations · NCT06950892

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.